ESMO 2018: Abstracts

Abstract submission deadlines

Deadline Date and time
Abstracts
Intent to submit LBA
Trial in Progress
09 May 2018, 21:00hrs CEST (Central European Summer Time)
Final Late-breaking abstracts (LBA) Final submission deadline 17 September 2018 21:00hrs CEST (Central European Summer Time)

Submit Your Abstract

Late-breaking abstracts (LBA)

Late-breaking abstracts may be submitted for high quality, new research findings with implications for clinical practice or understanding of disease processes. 

Only abstracts for which no conclusive data are available at the time of the abstract submission deadline of 09 May 2018 will be considered for late-breaking status.

 A skeleton indicating the type of data that will be available by the late-breaking abstract deadline must be submitted online by the regular abstract deadline.

Submitters of preliminary versions receiving approval to proceed must submit the final LBA by 17 September 2017, 21:00 CEST (Central European Summer Time)

Trial in progress abstracts (TiP)

Trial in Progress abstracts in all phases of clinical research (phases I to III) may be submitted to Munich 2018.

It is expected that abstracts submitted as Trial in Progress are ongoing trials that have not reached any protocol-specified endpoints for analysis and consequently will only require the completion of two (2) sections: Background and Trial design. Abstracts including results or preliminary data will be rejected

Recruitment must have already begun or have been completed by the abstract submission deadline of 09 May 2018.

Encore TiP abstracts will NOT be accepted.

Trial in Progress abstracts will not be considered for Proffered Paper (oral) presentation. 

Presentation and publication of accepted abstracts

The ESMO 2018 Scientific Committee will select abstracts for presentation during the Congress based on the following possibilities:

  • Presidential Symposium – Oral presentations by authors of the very best submitted abstracts containing cutting-edge and significant clinical practice-changing studies, followed by expert discussion and perspectives.
  • Proffered Paper – Oral presentations by authors presenting original data of superior quality, followed by expert discussion and perspectives.
  • Poster Discussion – Presentation and analysis by an invited speaker highlighting important findings within a disease type or about a common theme plus interactive audience discussion. Poster Discussion posters will be displayed for the duration of the Congress, subject to the embargo policy, ie Late-Breaking Abstracts may only be displayed from the embargo time detailed in the schedule below.
  • Poster – Display sessions for review, discussion and questions. Rotated by category, posters will be displayed for one day of the Congress and the presenting authors must be available for Q&A for one hour to represent their work. 

All accepted abstracts, including Late-breaking, will be published online only in the ESMO 2018 Abstract Book, a supplement to the official ESMO journal Annals of Oncology.

Detailed instructions for the preparation of visual presentations and posters will be made available on the ESMO Web site in August 2018 along with scheduling notices.

Travel grants

A restricted number of travel grants to ESMO 2018 are available, upon application, to first author (= presenter) of candidates under the age of 40 who submit abstracts considered deserving of recognition. Selection will be made by the ESMO 2018 Scientific Committee on a competitive basis from among the accepted abstracts.

To apply for a travel grant, the following documents must be received by the ESMO Congress Department on or before 09 May 2018:

  • A letter of introduction by the applicant. Please include the following general information:
    • How relevant are the topics presented during this Congress to your current practice and research?
    • Have you attended any event on a similar topic in the last 3 years?
    • How do you believe your attendance at this Congress will help you improve your knowledge in the field and your professional development?
    • How do you consider that the findings published in your abstract make a relevant contribution to the topics presented during this Congress?
    • Have you recently been awarded an ESMO travel grant? If yes, for which event?
  • A copy of the submitted abstract (the applicant must be the first author and presenter)
  • A readable photocopy of either identity card or passport
  • A short curriculum vitae (maximum 2 pages) 

Documentation must be sent by E-mail to travelgrants@esmo.org

The ESMO 2018 organisers will provide the recipients with a subsidised travel ticket, subsidised accommodation and Congress registration.

Travel grant recipients must submit a report detailing the benefits of participating in ESMO 2018 by 23 November 2018.

Incomplete applications will not be considered.